论文部分内容阅读
目的:探究老年2型糖尿病并发慢性心力衰竭的临床治疗体会。方法:在基础治疗的前提下,对照组给予美托洛尔治疗,观察组给予卡维地洛治疗。给药观察1年,观察两组治疗前后LVEDD、LVESD、LVEF的变化,并对比两组治疗前后心功能、实验室检查、心脏事件的发生率。结果:观察组总有效率为89.02%,明显优于对照组70.73%,差异有统计学意义,P<0.05。对照组出现心脏事件、发生心力衰竭17例(占20.73%),明显高于观察组6例(占7.32%),差异有统计学意义,P<0.05。两组治疗后FPG、LDL-C、Ccr实验室检查无明显差异,P<0.05。观察组治疗后LVEF、LVEDD、LVESD心功能对比,明显优于对照组,差异具有统计学意义,P<0.05。结论:对老年2型糖尿病并发慢性心力衰竭患者给予卡维地洛的临床治疗效果确切,不但能够有效改善患者的心脏功能,而且不影响血糖、血脂变化,能够有效降低发生慢性心力衰竭事件的几率,用药安全可靠,值得临床应用与推广。
Objective: To explore the clinical treatment of senile type 2 diabetes complicated with chronic heart failure. Methods: Under the premise of basic treatment, metoprolol was given to the control group and carvedilol was given to the observation group. The administration was observed for 1 year. The changes of LVEDD, LVESD and LVEF before and after treatment were observed. The incidences of heart function, laboratory tests and cardiac events were compared between the two groups before and after treatment. Results: The total effective rate in the observation group was 89.02%, which was significantly better than that in the control group (70.73%), the difference was statistically significant (P <0.05). In the control group, 17 cases (20.73%) had heart failure and heart failure, which was significantly higher than that in the observation group (7.32%), the difference was statistically significant (P <0.05). There was no significant difference between the two groups in the laboratory test of FPG, LDL-C and Ccr after treatment (P <0.05). The comparison of cardiac function of LVEF, LVEDD and LVESD in observation group was better than that in control group, the difference was statistically significant (P <0.05). Conclusion: The clinical treatment of carvedilol in elderly patients with type 2 diabetes mellitus complicated with chronic heart failure is effective. It not only can effectively improve the cardiac function but also does not affect the changes of blood glucose and blood lipids, and can effectively reduce the incidence of chronic heart failure , Safe and reliable medication, it is worth clinical application and promotion.